Non‑Invasive Prenatal Testing (NIPT) is a screening test performed from a maternal blood sample to assess the chance of your baby having certain chromosome conditions such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18) or Patau syndrome (Trisomy 13). It analyses small fragments of fetal DNA in your bloodstream that come from the placenta, offering a highly accurate estimate of risk without posing any harm to your pregnancy.
Yes, NIPT is considered safe because it involves only a routine blood test from the mother’s arm and does not involve procedures that could increase the risk to the pregnancy. It can usually be performed from around 10 weeks’ gestation onwards. The test can screen for selected chromosome differences early in pregnancy, helping you make informed choices about further testing or care.
NIPT results indicate a higher or lower chance of certain chromosome conditions, but they are not a definitive diagnosis. A high‑chance result means there is an increased likelihood of a condition, and your healthcare provider may recommend diagnostic tests like CVS or amniocentesis to confirm a diagnosis. A low‑chance result makes those conditions very unlikely but does not rule out all possible genetic or physical abnormalities. Because NIPT is a screening tool, it works best alongside routine ultrasounds and standard antenatal care.
